Coffee and Cirrhosis: Why Two Cups a Day May Keep Your Liver Healthy?
Regular coffee consumption (2-3 cups/day) protects against liver cirrhosis, reduces fibrosis, prevents liver cancer, and ...
Too Old to Operate2d
GALAD Score for Diagnosing HCC in Cirrhosis and Predicting Tumor Characteristics
The following is a summary of “Evaluating the GALAD Score for Detection of Hepatocellular Carcinoma in Patients With ...
HealthDay on MSN1d
Prevalence of Cirrhosis Higher for Trans- Versus Cisgender Adults
Trans- versus cisgender adults have an increased prevalence of cirrhosis but similar five-year survival, according to a study ...
Press release: Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis
Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosisalfapump® is ...
Daily5d
Gluten-free diet improves celiac disease associated with cryptogenic cirrhosis, suggests study
Researchers have discovered that patients who also have biopsy-proven celiac disease (CeD) with cryptogenic cirrhosis benefit ...
The Herald Journal11d
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment ...
Medical Xpress on MSN12d
Exploring the heterogeneity of metabolic dysfunction-associated steatotic liver disease
More information: Norbert Stefan et al, Metabolic dysfunction-associated steatotic liver disease: heterogeneous ...
Galectin Therapeutics Shares Drop 54% After Treatment Misses Trial Endpoint
Galectin Therapeutics shares fell after it said the endpoint of a liver-disease treatment trial didn't meet statistical significance. The stock lost more than half its value, falling to about 91 cents ...
News Medical on MSN12d
Revolutionizing MASLD treatment with GLP-1 receptor agonists
Researchers explore the therapeutic potential and clinical insights of GP1-RAs in the management of metabolic ...